The Dreyer Peptide and Protein Sequencer

Credit: Courtesy of Alan Hawk / Historical Collections National Museum of Health and Medicine" /> Credit: Courtesy of Alan Hawk / Historical Collections National Museum of Health and Medicine As biochemists during the 1970s delved into the protein chemistry of cell signaling, cycling, and adhesion, they ran into two major obstacles: getting enough purified material for some proteins, and the low molecular weights of others. Interferon, for example, was so difficult to purify that it

Written byTerry Sharrer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As biochemists during the 1970s delved into the protein chemistry of cell signaling, cycling, and adhesion, they ran into two major obstacles: getting enough purified material for some proteins, and the low molecular weights of others. Interferon, for example, was so difficult to purify that it took more than two decades before its structural characterization. And tiny proteins like angiotensin II (8 amino acids) and the antidiuretic hormone vasopressin (9 amino acids) produced hard-to-interpret protein signatures.

Biochemists were constantly pushing the limits of technology to couple, cleave, extract, and sequence peptides with better sensitivity. Pehr Edman, in 1950, developed a chemical degradation process for amino acid sequencing and built the first automated "sequenator" for that task in 1967. Richard Laursen, at Boston University, improved on Edman's concept in 1971 by immobilizing the study sample on a resin support. This made it possible to investigate smaller peptides, but liquid solvents in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies